BCMA-Targeting CARs With Optimized Variable Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting B-cell maturation antigen (BCMA) for cancer treatment have shown limited success, highlighting the need for more effective BCMA-targeting therapeutic options.
Innovation Solution
Development of novel antibodies and chimeric antigen receptors (CARs) specifically binding to BCMA, combined with genetically engineered immune effector cells, to enhance cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BCMA-targeting therapies are used, then treatment is provided, but therapeutic efficacy is limited
Solution Approach 1:
The patent modifies the binding parameters of BCMA-targeting antibodies by engineering chimeric antigen receptors with optimized variable regions (SEQ ID NOs: 1-8) to achieve higher binding affinity and specificity, directly addressing the limited therapeutic efficacy of current therapies
Solution Approach 2:
The invention creates composite chimeric antigen receptors that combine BCMA-specific antibody variable regions with T-cell receptor signaling domains, generating a hybrid molecule that enhances both binding reliability and cytolytic productivity against BCMA-expressing tumors
2Reliability
If novel antibodies with improved binding affinity are developed, then therapeutic potential is enhanced, but development complexity increases
Solution Approach 1:
The patent segments the antibody structure into distinct functional modules: variable regions (SEQ ID NOs: 1-8) for antigen binding, constant regions for effector functions, and linker regions for structural stability, allowing independent optimization of each segment to achieve high binding affinity without overwhelming complexity
Solution Approach 2:
The engineered antibodies are designed with universal frameworks that can be applied across different BCMA-targeting therapies, using standardized variable region sequences (SEQ ID NOs: 1-8) that provide improved binding affinity while maintaining compatibility with various antibody formats and delivery systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antibodies and BCMA-targeting CARs demonstrate improved binding affinity and therapeutic potential, offering enhanced treatment options for BCMA-expressing cancers, such as multiple myeloma, by specifically engaging cancer cells and inducing cytolytic activities.
Implementation Method 1
antibodies or antigen-binding fragments thereof that specifically binds BCMA
Implementation Method 2
inducing cytolytic activities
Data Source
AI summary
Disclosed herein are anti-BCMA antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-BCMA antibodies and antigen-binding fragments (“BCMA CARs”) and genetically modified immune effector cells having such BCMA CARs. Polynucleotides encoding the anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. Compositions comprising anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. The present disclosure also relates to use of the anti-BCMA antibodies and antigen-binding fragments and genetically modified immune effector cells having such BCMA CARs in cancer treatment.